Liposome Treatment
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
19
NCT02583373
Safety, Tolerability, Efficacy and Pharmacodynamics of CAL02 in Severe Pneumonia Caused by Streptococcus Pneumoniae
Phase: Phase 1
Role: Lead Sponsor
Start: Mar 21, 2016
Completion: Feb 20, 2018
Loading map...